At the American Diabetes Association鈥檚 83rd Scientific Sessions, and took another step in the obesity arena with data presentations on their respective glucagon-like peptide receptor 1 agonist (GLP1RA) trials for diabetes and obesity management.
Boehringer鈥檚 survodutide (BI 456906) is a subcutaneous long-acting dual glucagon and GLP-1 agonist that requires administration once weekly. The Germany-based company is developing the therapy with for people living with obesity or who have a body mass index (BMI) exceeding 27kg/m虏 and for treating non-alcoholic steatohepatitis (NASH).
Data from the Phase II dose-finding trial (NCT04667377) showed a dose-response relationship with higher doses of survodutide, which lead to increased weight loss. Furthermore, 82.8% of the participants in the 4.8mg survodutide group achieved a weight loss of at least 5% at week 46 in comparison to 25.9% in the placebo group. The company reported that 90.9% of participants in the survodutide group had adverse events in comparison to 75.3% of the placebo group. Additionally, the drug has shown a nearly 19% efficacy for weight loss in overweight or obese people, as per a 23 June Zealand Pharma release.
, Dr Carel le Roux, the principal investigator of the trial explained the drug鈥檚 mechanism saying, 鈥淏y activating both the glucagon and GLP-1 receptors, survodutide may inhibit both appetite and improve energy expenditure.鈥�
Survodutide is being developed under a between the two companies where Boehringer finances all research, development and commercialisation activities. This partnership uses Zealand鈥檚 experience in developing peptide-based medicines and the company could possibly receive up to 鈧�345m ($376.1m).
Boehringer aims to follow the success of other high-profile drugs such as 鈥檚 GLP1RA Ozempic (semaglutide). The US Food and Drug Administration first approved the drug in December 2017 for improving glycaemic control in adults with type 2 diabetes (T2D). Novo Nordisk has received approval for once-daily semaglutide tablets for the treatment of T2D in the US, the EU and some other countries under the brand name Rybelsus.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAt the same conference, Novo Nordisk from the Phase IIIb PIONEER trial (NCT04707469), showing that Ozempic caused a mean haemoglobin A1C (HbA1c) reduction of up to 2% points. GlobalData predicts that the therapy will generate $71bn in US sales between 2023 and 2029.
GlobalData is the parent company of 污污漫畫 Technology.
This article was updated with the correct indication for Novo Nordisk’s Ozempic.
